2. Search Result
Search Result
Results for "

CSF1R+inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114153
    PLX5622
    Maximum Cited Publications
    89 Publications Verification

    		 c-Fms Neurological Disease
    PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm [1] .
    PLX5622
  • HY-153920
    Pimicotinib

    ABSK021

    		 c-Fms c-Kit PDGFR Cancer
    Pimicotinib (ABSK021) is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production). Pimicotinib exhibits anti-tumor activity [1] .
    Pimicotinib
  • HY-10408
    Ki20227
    4 Publications Verification

    		 c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction [1].
    Ki20227
  • HY-114153A
    PLX5622 hemifumarate
    Maximum Cited Publications
    89 Publications Verification

    		 c-Fms Neurological Disease
    PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 hemifumarate demonstrates desirable PK properties in varies animals [1] .
    PLX5622 hemifumarate
  • HY-101774
    CSF1R-IN-1
    1 Publications Verification

    		 c-Fms Cancer
    CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
    CSF1R-IN-1
  • HY-101768
    PRN1371
    1 Publications Verification

    		 FGFR c-Fms Cancer
    PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively [1].
    PRN1371
  • HY-109086
    Edicotinib
    3 Publications Verification

    JNJ-40346527; JNJ-527

    		 c-Fms Neurological Disease Inflammation/Immunology Cancer
    Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively [1]. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research [1] .
    Edicotinib
  • HY-117244
    AZD7507
    2 Publications Verification

    		 c-Fms Cancer
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
    AZD7507
  • HY-159838
    Enrupatinib

    EI‐1071

    		 c-Fms Amyloid-β Neurological Disease Cancer
    Enrupatinib (EI‐1071) is a potent, orally active, CNS-penetrant and selective CSF1R inhibitor. Enrupatinib inhibits macrophage proliferation and osteoclast differentiation in vitro. Enrupatinib preserves microglia distal to Aβ plaques. Enrupatinib mitigates Alzheimer's disease (AD)-related pathologies by reducing neuroinflammation, preserving neuronal integrity, lowering disease-associated microglia gene expression, and enhancing cognitive function in 5xFAD and J20 mouse models. Enrupatinib reduces tumor-associated macrophage infiltration and enhances antitumor activity of anti-PD-1 antibody in murine colorectal cancer and breast cancer models. Enrupatinib can be used for the research of AD, colorectal cancer, and breast cancer [1] .
    Enrupatinib
  • HY-160842
    CSF1R-IN-24

    		c-Fms Neurological Disease
    CSF1R-IN-24 (Example 134) is an orally active CSF1R inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG) [1].
    CSF1R-IN-24
  • HY-132935
    BPR1R024

    		c-Fms Inflammation/Immunology Cancer
    BPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology [1].
    BPR1R024
  • HY-159108
    AZ683

    		c-Fms Cardiovascular Disease
    AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (Ki=8 nM; IC50=6 nM). AZ683 has good oral bioavailability. [ 11C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) [1] .
    AZ683
  • HY-174366
    JMC14

    		c-Fms PI3K Cancer
    JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity [1].
    JMC14
  • HY-101526
    GENZ-882706

    RA03546849

    		 c-Fms Inflammation/Immunology
    GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
    GENZ-882706
  • HY-153012
    Axl/Mer/CSF1R-IN-1

    		TAM Receptor c-Fms Cancer
    Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM [1].
    Axl/Mer/CSF1R-IN-1
  • HY-139990
    CSF1R-IN-3
    1 Publications Verification

    		 c-Fms Cancer
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity [1].
    CSF1R-IN-3
  • HY-147609
    CSF1R-IN-8

    		c-Fms Cancer
    CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM [1].
    CSF1R-IN-8
  • HY-147611
    CSF1R-IN-10

    		c-Fms Cancer
    CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM [1].
    CSF1R-IN-10
  • HY-153243
    IACS-9439

    		c-Fms Cancer
    IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a Ki value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research [1].
    IACS-9439
  • HY-153920A
    Pimicotinib hydrochloride

    ABSK021 hydrochloride

    		 c-Fms c-Kit PDGFR Cancer
    Pimicotinib (ABSK021) hydrochloride is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production). Pimicotinib hydrochloride exhibits anti-tumor activity [1] .
    Pimicotinib hydrochloride
  • HY-109086A
    Edicotinib hydrochloride

    JNJ-40346527 hydrochloride; JNJ-527 hydrochloride

    		 c-Fms Neurological Disease Inflammation/Immunology Cancer
    Edicotinib hydrochloride is a potent, selective, brain penetrant and orally active?colony-stimulating factor-1 receptor (CSF-1R)?inhibitor with an IC50 of 3.2 nM. Edicotinib hydrochloride exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively [1]. Edicotinib hydrochloride limits microglial expansion and attenuates microglial proliferation and neurodegeneration?in mice. Edicotinib hydrochloride has the potential for Alzheimer’s disease and rheumatoid arthritis research [1] .
    Edicotinib hydrochloride
  • HY-153277
    Axl/Mer/CSF1R-IN-2

    		TAM Receptor c-Fms Neurological Disease
    Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor [1].
    Axl/Mer/CSF1R-IN-2
  • HY-147610
    CSF1R-IN-9

    		c-Fms Cancer
    CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC50 of 0.028 μM [1].
    CSF1R-IN-9
  • HY-147608
    CSF1R-IN-7

    		c-Fms Neurological Disease
    CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research [1].
    CSF1R-IN-7
  • HY-158363
    CSF1R-IN-25

    		c-Fms Neurological Disease Inflammation/Immunology Cancer
    CSF1R-IN-25 (compound 36) is an orally effective CSF1R inhibitor. CSF1R-IN-25 can be used to study cancer, inflammation, and neurodegeneration [1].
    CSF1R-IN-25
  • HY-162309
    CSF1R-IN-20

    		c-Fms Cancer
    CSF1R-IN-20 (compound 7a) is a CSF-1R Inhibitor with an IC50 value of 467 nM. CSF1R-IN-20 inhibits CSF-1R auto-phosphorylation [1].
    CSF1R-IN-20
  • HY-161084
    CSF1R-IN-18

    		c-Fms Neurological Disease Cancer
    CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases [1].
    CSF1R-IN-18
  • HY-157996
    CSF1R-IN-21

    		c-Fms Neurological Disease
    CSF1R-IN-21 (compound 7e) is a CSF-1R Inhibitor with an IC50 value of 31 nM. CSF1R-IN-21 inhibits CSF-1R auto-phosphorylation and can be used for the research of neurodegenerative diseases [1].
    CSF1R-IN-21
  • HY-132935A
    BPR1R024 mesylate

    		c-Fms Inflammation/Immunology Cancer
    BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 mesylate is the equivalent of BPR1R024 (HY-132935). BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology [1].
    BPR1R024 mesylate
  • HY-101774R
    CSF1R-IN-1 (Standard)

    		Reference Standards c-Fms Cancer
    CSF1R-IN-1 (Standard) is the analytical standard of CSF1R-IN-1 (HY-101774). This product is intended for research and analytical applications. CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
    CSF1R-IN-1 (Standard)
  • HY-101768R
    PRN1371 (Standard)

    		Reference Standards FGFR c-Fms Cancer
    PRN1371 (Standard) is the analytical standard of PRN1371 (HY-101768). This product is intended for research and analytical applications. PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively [1].
    PRN1371 (Standard)
  • HY-10408R
    Ki20227 (Standard)

    		Reference Standards c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 (Standard) is the analytical standard of Ki20227 (HY-10408). This product is intended for research and analytical applications. Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction [1].
    Ki20227 (Standard)
  • HY-183569
    CSF1R-IN-27

    		c-Fms Akt PERK Aminotransferases (Transaminases) Apoptosis TNF Receptor Interleukin Related Metabolic Disease
    CSF1R-IN-27 is a CSF1R inhibitor with oral effectiveness, kinome-wide selective profile, low cellular cytotoxicity, and CSF1R IC50 values of 19 nM, 88 nM, 173 nM, 797 nM, 1448 nM, and >3000 nM. CSF1R-IN-27 suppresses M-CSF-induced phosphorylation of CSF1R, AKT, and ERK in macrophages, and inhibits hepatic p-CSF1R/p-AKT/p-ERK signaling. CSF1R-IN-27 reduces serum transaminase levels, improves hepatic histopathology, alleviates inflammatory cell infiltration, and decreases circulating TNF-α and IL-6 levels. CSF1R-IN-27 can be used for the research of acute liver injury [1].
    CSF1R-IN-27

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: